ESLA

Estrella Immunopharma, Inc. NASDAQ Listed Sep 14, 2021

Healthcare ·Biotechnology ·US · estrellabio.com

$0.98

-5.53% vs $1.04

Mkt Cap $36.2M

52w Low $0.82 7.3% of range 52w High $3.05

50d MA $1.21 200d MA $1.44

P/E (TTM) -2.8x

EV/EBITDA —

P/B —

Debt/Equity 0.0x

ROE 126.0%

P/FCF -20.3x

RSI (14) 41.40

ATR (14) $0.08

Beta 0.58

50d MA $1.21

200d MA $1.44

Avg Volume 42.5K

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

CIK (SEC)

1844417

Phone

510 318 9098

5858 Horton Street · EmeryVille, CA 94608 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 18, 2026	AMC	-0.18	-0.02	+91.0%	1.08	+0.9%	+1.9%	-5.5%	-1.9%	-4.4%	+0.5%	—
Nov 12, 2025	AMC	-0.19	-0.13	+30.3%	2.10	+3.3%	+4.8%	+3.2%	-18.1%	-2.2%	-3.8%	—
Aug 11, 2025	AMC	-0.07	-0.15	-114.3%	0.86	-1.7%	+0.0%	-1.8%	+1.3%	+5.8%	+1.0%	—
May 14, 2025	AMC	-0.11	-0.06	+45.5%	0.99	-0.3%	-5.0%	+2.0%	+2.2%	-0.1%	+3.1%	—
Feb 15, 2025	AMC	-0.12	-0.03	+76.2%	—	—	—	—	—	—	—	—
Nov 14, 2024	AMC	—	-0.09	—	0.84	-6.0%	+6.0%	-0.0%	-4.4%	+8.2%	-3.3%	—
Sep 27, 2024	AMC	—	-0.13	—	1.19	-2.5%	-2.5%	+10.3%	-3.1%	-10.5%	+3.6%	—
May 14, 2024	AMC	—	-0.01	—	1.05	+7.6%	+2.9%	-2.8%	-3.8%	+4.0%	+0.0%	—
Feb 14, 2024	AMC	—	-0.03	—	1.08	+4.6%	+0.9%	+0.9%	-3.6%	-1.9%	-2.9%	—
Sep 30, 2023	AMC	—	-1.78	—	—	—	—	—	—	—	—	—
Jun 29, 2023	AMC	—	-0.03	—	10.81	+0.4%	+0.3%	+0.5%	+0.0%	+0.0%	+0.1%	—
Mar 30, 2023	AMC	—	-0.03	—	10.58	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Feb 9	D. Boral Capital	Maintains	Buy → Buy	—	$1.45	$1.34	-7.6%	-1.4%	-3.5%	-5.8%	-5.4%	+2.4%
Jan 28	D. Boral Capital	Maintains	Buy → Buy	—	$1.07	$1.09	+1.9%	-0.9%	+1.9%	+3.7%	-2.7%	+7.3%
Nov 3	D. Boral Capital	Maintains	Buy → Buy	—	$2.42	$2.43	+0.4%	+26.0%	-24.9%	+11.8%	+7.8%	+6.2%
Aug 12	D. Boral Capital	Maintains	Buy → Buy	—	$0.86	$0.85	-1.7%	+0.0%	-1.8%	+1.3%	+5.8%	+1.0%
Jun 3	D. Boral Capital	Maintains	Buy → Buy	—	$0.97	$1.10	+13.4%	-14.0%	+18.7%	+7.1%	+0.9%	-7.6%
May 29	D. Boral Capital	Maintains	Buy → Buy	—	$0.97	$0.97	+0.0%	+5.2%	-1.0%	-4.0%	-14.0%	+18.7%
Feb 21	D. Boral Capital	Maintains	Buy → Buy	—	$1.49	$1.69	+13.4%	-0.7%	-10.8%	-12.1%	-5.2%	-12.7%

Date	Insider	Title	Type	Shares	Price	Value	Owned After	D1%	D5%
Oct 7, 2025	Xu JiandongOff	Chief Financial Officer	Buy	1,000	$1.33	$1K	265,488	+11.56%	-7.80%
Sep 22, 2025	Xu JiandongOff	Chief Financial Officer	Buy	1,000	$1.16	$1K	16,700	+11.56%	-7.80%
Sep 11, 2025	Xu JiandongOff	Chief Financial Officer	Buy	100	$1.04	$104	264,588	+11.56%	-7.80%

Institutional (13F) — Top 9 All ↗

#	Manager	Shares	Value	Chg	Period
1	Vanguard Capital Management Llc	382,469	$405K	New	Mar 2026
2	Wells Fargo & Company/mn	264,388	$280K	New	Mar 2026
3	Renaissance Technologies Llc	62,795	$67K	Reduced	Mar 2026
4	Morgan Stanley	22,194	$35K	New	Dec 2025
5	Northern Trust Corp	19,624	$21K	—	Mar 2026
6	Jane Street Group, Llc	10,441	$16K	New	Dec 2025
7	Ubs Group Ag	15,079	$16K	Added	Mar 2026
8	Royal Bank Of Canada	6,600	$7K	—	Mar 2026
9	Wolverine Asset Management Llc	468	$496	New	Mar 2026

Mutual Funds / ETFs (N-PORT) — Top 5 All ↗

#	Fund	Shares	Value	Period
1	Fidelity Extended Market Index Fund	62,562	$76K	Feb 2026
2	iShares Micro-Cap ETF	37,765	$40K	Mar 2026
3	Fidelity Total Market Index Fund	16,762	$20K	Feb 2026
4	Fidelity Series Total Market Index Fund	12,628	$15K	Feb 2026
5	Fidelity Nasdaq Composite Index Fund	1,582	$2K	Feb 2026

Data updated apr 25, 2026 7:41am · Source: financialmodelingprep.com